WO2012105475A1 - 悪液質の治療又は予防剤 - Google Patents
悪液質の治療又は予防剤 Download PDFInfo
- Publication number
- WO2012105475A1 WO2012105475A1 PCT/JP2012/051937 JP2012051937W WO2012105475A1 WO 2012105475 A1 WO2012105475 A1 WO 2012105475A1 JP 2012051937 W JP2012051937 W JP 2012051937W WO 2012105475 A1 WO2012105475 A1 WO 2012105475A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cachexia
- compound
- general formula
- agent
- therapeutic
- Prior art date
Links
- QFPPWGZZBMRWEO-NENRXHGPSA-N CN([C@H](CC[C@@]([C@@H]1N(CC2CC2)C[C@@]1(C1)C2)([C@]11c3c2cc2)O)[C@@H]1Oc3c2O)C(/C=C/c1c[o]cc1)=O Chemical compound CN([C@H](CC[C@@]([C@@H]1N(CC2CC2)C[C@@]1(C1)C2)([C@]11c3c2cc2)O)[C@@H]1Oc3c2O)C(/C=C/c1c[o]cc1)=O QFPPWGZZBMRWEO-NENRXHGPSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
Abstract
Description
[1]
下記一般式(I)
で表される化合物又はその薬理学的に許容される酸付加塩を有効成分として含有する悪液質の治療又は予防剤。
[2]
一般式(I)において、R1が、シクロプロピルメチル、シクロブチルメチル、シクロペンチルメチル又はシクロヘキシルメチルであり、R2が、メチル、エチル又はプロピルである、[1]記載の悪液質の治療又は予防剤。
[3]
一般式(I)において、R1が、シクロプロピルメチルであり、R2が、メチルであり、Bが、トランス型の-CH=CH-である、[1]記載の悪液質の治療又は予防剤。
[4]
一般式(I)で表される化合物が、(-)-17-(シクロプロピルメチル)-3,14β-ジヒドロキシ-4,5α-エポキシ-6β-[N-メチル-トランス-3-(3-フリル)アクリルアミド]モルヒナン
[5]
悪液質が、がん悪液質である、[1]から[4]のいずれか一項記載の悪液質の治療又は予防剤。
で表される化合物又はその薬理学的に許容される酸付加塩を有効成分として含有する。
B16/F10 melanoma細胞の継代は、10%FCS含有RPMI1640培地を用いて行った。薬効評価には、4週齢の雄性C57BL/6マウス(日本エスエルシー)を購入し、3週間の馴化の後に使用した。悪液質モデル動物の作製は、以下のようにして行った。すなわち、B16/F10 melanoma細胞をマウスの足蹠に1匹あたり4×105個ずつ移植した。細胞移植から3週間後、腫瘍体積がある程度大きくなったことを確認し、悪液質モデル動物とした。また、腫瘍体積を測定して各群腫瘍体積の平均が均等になるよう群分けを行った。悪液質に対する治療効果の検討は、以下のようにして行った。
生理食塩水投与群の生存期間に対し、化合物1の投与は統計学的に有意な延長作用(p=0.0335:カプランマイヤー法ログランク検定)を示した。これに対し、CI-977及びモルヒネの投与は、生存期間の短縮傾向を示した。また、生理食塩水投与群の体重減少に対し、化合物1及びCI-977の投与は、統計学的に有意な抑制作用(化合物1 30μg/kg p=0.0365、化合物1 100μg/kg p=0.0007、CI-977 p=0.0009:経時型多重比較(Dunnett型比較))を示したが、モルヒネの投与はさらなる体重減少傾向を示した。
Claims (5)
- 一般式(I)において、R1が、シクロプロピルメチル、シクロブチルメチル、シクロペンチルメチル又はシクロヘキシルメチルであり、R2が、メチル、エチル又はプロピルである、請求項1記載の悪液質の治療又は予防剤。
- 一般式(I)において、R1が、シクロプロピルメチルであり、R2が、メチルであり、Bが、トランス型の-CH=CH-である、請求項1記載の悪液質の治療又は予防剤。
- 悪液質が、がん悪液質である、請求項1から4のいずれか一項記載の悪液質の治療又は予防剤。
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA2825165A CA2825165C (en) | 2011-01-31 | 2012-01-30 | Therapeutic or prophylactic agent for cachexia |
JP2012507744A JP5929753B2 (ja) | 2011-01-31 | 2012-01-30 | 悪液質の治療又は予防剤 |
MX2013008749A MX2013008749A (es) | 2011-01-31 | 2012-01-30 | Agente terapeutico o profilactico para caquexia. |
ES12742214.5T ES2586655T3 (es) | 2011-01-31 | 2012-01-30 | (-)-17-(ciclopropilmetil)-3,14beta-dihidroxi-4,5alfa-epoxi-6beta-[N-metil-trans-3-(3-furil)acrilamido]morfinano para su utilización en el tratamiento o prevención de la caquexia por cáncer |
US13/982,578 US9006262B2 (en) | 2011-01-31 | 2012-01-30 | Therapeutic or prophylactic agent for cachexia |
EP12742214.5A EP2671585B1 (en) | 2011-01-31 | 2012-01-30 | (-)-17-(cyclopropylmethyl)-3,14ß-dihydroxy-4,5a-epoxy-6ß-[N-methyl-trans-3-(3-furyl)acrylamido]morphinan for use in treating or preventing cancer cachexia |
CN201280007167.XA CN103327977B (zh) | 2011-01-31 | 2012-01-30 | 恶液质的治疗或预防剂 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2011-018021 | 2011-01-31 | ||
JP2011018021 | 2011-01-31 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2012105475A1 true WO2012105475A1 (ja) | 2012-08-09 |
Family
ID=46602689
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2012/051937 WO2012105475A1 (ja) | 2011-01-31 | 2012-01-30 | 悪液質の治療又は予防剤 |
Country Status (8)
Country | Link |
---|---|
US (1) | US9006262B2 (ja) |
EP (1) | EP2671585B1 (ja) |
JP (1) | JP5929753B2 (ja) |
CN (1) | CN103327977B (ja) |
CA (1) | CA2825165C (ja) |
ES (1) | ES2586655T3 (ja) |
MX (1) | MX2013008749A (ja) |
WO (1) | WO2012105475A1 (ja) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016152965A1 (ja) * | 2015-03-24 | 2016-09-29 | 東レ株式会社 | 低アルブミン血症の改善剤 |
WO2021079978A1 (ja) | 2019-10-24 | 2021-04-29 | 東レ株式会社 | 悪液質の治療剤又は予防剤 |
WO2022004788A1 (ja) | 2020-06-30 | 2022-01-06 | 東レ株式会社 | 代謝異常を伴う疾患又は症候群における筋力低下症状の改善剤又は予防剤 |
WO2022225045A1 (ja) | 2021-04-23 | 2022-10-27 | 東レ株式会社 | グレリン抵抗性を伴う悪液質の治療剤又は予防剤 |
US11897871B1 (en) | 2021-06-14 | 2024-02-13 | Scorpion Therapeutics, Inc. | Methods for treating cancer |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103261203B (zh) * | 2010-10-19 | 2017-06-20 | 纪念斯隆-凯特琳癌症中心 | 用于治疗疼痛的4,5a‑环氧基吗啡喃的6‑酰氨基衍生物 |
EP4212532A3 (en) | 2015-04-30 | 2023-09-27 | Memorial Sloan Kettering Cancer Center | Mitragynine analogs and uses thereof |
WO2019171333A1 (en) | 2018-03-08 | 2019-09-12 | Victoria Link Ltd | Treatment of demyelinating diseases |
US10799496B2 (en) | 2018-07-13 | 2020-10-13 | Alkermes Pharma Ireland Limited | Naphthylenyl compounds for long-acting injectable compositions and related methods |
US10807995B2 (en) | 2018-07-13 | 2020-10-20 | Alkermes Pharma Ireland Limited | Thienothiophene compounds for long-acting injectable compositions and related methods |
WO2020094634A1 (en) | 2018-11-05 | 2020-05-14 | Alkermes Pharma Ireland Limited | Thiophene prodrugs of naltroxene for long-acting injectable compositions and related methods |
WO2020205735A1 (en) * | 2019-03-29 | 2020-10-08 | Humanwell Pharmaceutical US | Novel morphinans useful for treating medical disorders |
EP4178666A1 (en) * | 2020-07-10 | 2023-05-17 | Duke University | Compositions and methods for treating cancer-associated cachexia |
Citations (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0543466A (ja) | 1991-08-19 | 1993-02-23 | Otsuka Pharmaceut Factory Inc | 悪液質改善治療剤 |
WO1993015081A1 (fr) | 1992-01-23 | 1993-08-05 | Toray Industries, Inc. | Derive de morphinane et utilisation en medicine |
WO1995001178A1 (fr) | 1993-06-30 | 1995-01-12 | Toray Industries, Inc. | Antitussif |
WO1995003307A1 (fr) | 1993-07-19 | 1995-02-02 | Toray Industries, Inc. | Agent de protection de cellules cerebrales |
WO1998023290A1 (fr) | 1996-11-25 | 1998-06-04 | Toray Industries, Inc. | Agent antiprurigineux |
WO1998051329A1 (fr) | 1997-05-15 | 1998-11-19 | Chugai Seiyaku Kabushiki Kaisha | Remede contre la cachexie |
WO1999005146A1 (fr) | 1997-07-25 | 1999-02-04 | Toray Industries, Inc. | Remedes contre l'hyponatremie |
WO1999011289A1 (fr) | 1997-09-02 | 1999-03-11 | Toray Industries, Inc. | Remedes contre la toxicomanie |
JP2000053572A (ja) | 1998-08-11 | 2000-02-22 | Toray Ind Inc | ORL1(opioid orphan)受容体拮抗薬 |
JP2000095685A (ja) | 1998-07-21 | 2000-04-04 | Sankyo Co Ltd | 悪液質の予防剤、又は治療剤 |
WO2001014383A1 (fr) | 1999-08-24 | 2001-03-01 | Toray Industries, Inc. | Remedes contre les douleurs neuropathiques et modeles animaux de douleurs neuropathiques |
JP2001163784A (ja) | 1999-12-06 | 2001-06-19 | Toray Ind Inc | 角膜または結膜用止痒剤 |
WO2002066475A2 (en) | 2001-02-23 | 2002-08-29 | Ligand Pharmaceuticals Incorporated | Tricyclic androgen receptor modulator compounds |
WO2002078744A1 (fr) | 2001-03-30 | 2002-10-10 | Toray Industries, Inc. | Remedes contre la psychonevrose |
WO2002089845A1 (en) | 2001-05-08 | 2002-11-14 | Toray Industries, Inc. | Remedies for sepsis |
WO2005097261A1 (en) | 2004-03-30 | 2005-10-20 | Sapphire Therapeutics, Inc. | Method of reducing c-reactive protein using growth hormone secretagogues |
WO2006095836A1 (ja) | 2005-03-10 | 2006-09-14 | Toray Industries, Inc. | 多発性硬化症に伴う痒みに対する止痒剤 |
WO2008133297A1 (ja) | 2007-04-24 | 2008-11-06 | Toray Industries, Inc. | ジスキネジアの治療または予防剤 |
WO2009001764A1 (ja) | 2007-06-22 | 2008-12-31 | Toray Industries, Inc. | 統合失調症の治療または予防剤 |
WO2009044883A1 (ja) | 2007-10-05 | 2009-04-09 | Toray Industries, Inc. | モルヒナン誘導体またはその薬理学的に許容される酸付加塩を有効成分とする皮膚性状改善治療薬 |
WO2011009020A2 (en) * | 2009-07-16 | 2011-01-20 | Mallinckrodt Inc. | Compounds and compositions for use in phototherapy and in treatment of ocular neovascular disease and cancers |
WO2011009015A1 (en) * | 2009-07-16 | 2011-01-20 | Mallinckrodt Inc. | (+) - morphinans as antagonists of toll-like receptor 9 and therapeutic uses thereof |
JP2011074018A (ja) | 2009-09-30 | 2011-04-14 | Toray Ind Inc | 線維筋痛症の治療剤又は予防剤 |
WO2011093441A1 (ja) | 2010-01-29 | 2011-08-04 | 東レ株式会社 | 胆道疾患の治療又は予防剤 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19939044A1 (de) * | 1999-08-18 | 2001-03-15 | Gruenenthal Gmbh | Verwendung von Morphinanderivaten als Arzneimittel |
-
2012
- 2012-01-30 CN CN201280007167.XA patent/CN103327977B/zh active Active
- 2012-01-30 WO PCT/JP2012/051937 patent/WO2012105475A1/ja active Application Filing
- 2012-01-30 US US13/982,578 patent/US9006262B2/en active Active
- 2012-01-30 MX MX2013008749A patent/MX2013008749A/es unknown
- 2012-01-30 EP EP12742214.5A patent/EP2671585B1/en active Active
- 2012-01-30 ES ES12742214.5T patent/ES2586655T3/es active Active
- 2012-01-30 JP JP2012507744A patent/JP5929753B2/ja active Active
- 2012-01-30 CA CA2825165A patent/CA2825165C/en active Active
Patent Citations (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0543466A (ja) | 1991-08-19 | 1993-02-23 | Otsuka Pharmaceut Factory Inc | 悪液質改善治療剤 |
WO1993015081A1 (fr) | 1992-01-23 | 1993-08-05 | Toray Industries, Inc. | Derive de morphinane et utilisation en medicine |
WO1995001178A1 (fr) | 1993-06-30 | 1995-01-12 | Toray Industries, Inc. | Antitussif |
WO1995003307A1 (fr) | 1993-07-19 | 1995-02-02 | Toray Industries, Inc. | Agent de protection de cellules cerebrales |
WO1998023290A1 (fr) | 1996-11-25 | 1998-06-04 | Toray Industries, Inc. | Agent antiprurigineux |
WO1998051329A1 (fr) | 1997-05-15 | 1998-11-19 | Chugai Seiyaku Kabushiki Kaisha | Remede contre la cachexie |
WO1999005146A1 (fr) | 1997-07-25 | 1999-02-04 | Toray Industries, Inc. | Remedes contre l'hyponatremie |
WO1999011289A1 (fr) | 1997-09-02 | 1999-03-11 | Toray Industries, Inc. | Remedes contre la toxicomanie |
JP2000095685A (ja) | 1998-07-21 | 2000-04-04 | Sankyo Co Ltd | 悪液質の予防剤、又は治療剤 |
JP2000053572A (ja) | 1998-08-11 | 2000-02-22 | Toray Ind Inc | ORL1(opioid orphan)受容体拮抗薬 |
WO2001014383A1 (fr) | 1999-08-24 | 2001-03-01 | Toray Industries, Inc. | Remedes contre les douleurs neuropathiques et modeles animaux de douleurs neuropathiques |
JP2001163784A (ja) | 1999-12-06 | 2001-06-19 | Toray Ind Inc | 角膜または結膜用止痒剤 |
WO2002066475A2 (en) | 2001-02-23 | 2002-08-29 | Ligand Pharmaceuticals Incorporated | Tricyclic androgen receptor modulator compounds |
WO2002078744A1 (fr) | 2001-03-30 | 2002-10-10 | Toray Industries, Inc. | Remedes contre la psychonevrose |
WO2002089845A1 (en) | 2001-05-08 | 2002-11-14 | Toray Industries, Inc. | Remedies for sepsis |
WO2005097261A1 (en) | 2004-03-30 | 2005-10-20 | Sapphire Therapeutics, Inc. | Method of reducing c-reactive protein using growth hormone secretagogues |
WO2006095836A1 (ja) | 2005-03-10 | 2006-09-14 | Toray Industries, Inc. | 多発性硬化症に伴う痒みに対する止痒剤 |
WO2008133297A1 (ja) | 2007-04-24 | 2008-11-06 | Toray Industries, Inc. | ジスキネジアの治療または予防剤 |
WO2009001764A1 (ja) | 2007-06-22 | 2008-12-31 | Toray Industries, Inc. | 統合失調症の治療または予防剤 |
WO2009044883A1 (ja) | 2007-10-05 | 2009-04-09 | Toray Industries, Inc. | モルヒナン誘導体またはその薬理学的に許容される酸付加塩を有効成分とする皮膚性状改善治療薬 |
WO2011009020A2 (en) * | 2009-07-16 | 2011-01-20 | Mallinckrodt Inc. | Compounds and compositions for use in phototherapy and in treatment of ocular neovascular disease and cancers |
WO2011009015A1 (en) * | 2009-07-16 | 2011-01-20 | Mallinckrodt Inc. | (+) - morphinans as antagonists of toll-like receptor 9 and therapeutic uses thereof |
JP2011074018A (ja) | 2009-09-30 | 2011-04-14 | Toray Ind Inc | 線維筋痛症の治療剤又は予防剤 |
WO2011093441A1 (ja) | 2010-01-29 | 2011-08-04 | 東レ株式会社 | 胆道疾患の治療又は予防剤 |
Non-Patent Citations (11)
Title |
---|
AM. J. MED., vol. 85, 1988, pages 289 - 291 |
BIOORG. MED. CHEM. LETT., vol. 5, 1995, pages 1505 - 1508 |
BR. J. PHARMACOL, vol. 101, 1990, pages 183 - 189 |
CHEM. PARHM. BULL., vol. 52, 2004, pages 664 - 669 |
CHEM. PHARM. BULL., vol. 52, 2004, pages 664 - 669 |
HETEROCYCLES, vol. 63, 2004, pages 865 - 870 |
J. CLIN. ONCOL., vol. 12, 1994, pages 213 - 225 |
J. NATL. CANCER INST., vol. 89, 1997, pages 1763 - 1773 |
J. PARENTERAL AND ENTERAL NUTRITION, vol. 12, pages 286 - 298 |
MASANORI FUKUSHIMA, MERCK MANUAL 18TH EDITION, 2007, pages 1234, XP008168959 * |
See also references of EP2671585A4 * |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016152965A1 (ja) * | 2015-03-24 | 2016-09-29 | 東レ株式会社 | 低アルブミン血症の改善剤 |
JPWO2016152965A1 (ja) * | 2015-03-24 | 2018-01-11 | 東レ株式会社 | 低アルブミン血症の改善剤 |
WO2021079978A1 (ja) | 2019-10-24 | 2021-04-29 | 東レ株式会社 | 悪液質の治療剤又は予防剤 |
KR20220087427A (ko) | 2019-10-24 | 2022-06-24 | 도레이 카부시키가이샤 | 악액질의 치료제 또는 예방제 |
WO2022004788A1 (ja) | 2020-06-30 | 2022-01-06 | 東レ株式会社 | 代謝異常を伴う疾患又は症候群における筋力低下症状の改善剤又は予防剤 |
KR20230031207A (ko) | 2020-06-30 | 2023-03-07 | 도레이 카부시키가이샤 | 대사이상을 수반하는 질환 또는 증후군에 있어서의 근력 저하 증상의 개선제 또는 예방제 |
WO2022225045A1 (ja) | 2021-04-23 | 2022-10-27 | 東レ株式会社 | グレリン抵抗性を伴う悪液質の治療剤又は予防剤 |
KR20240001121A (ko) | 2021-04-23 | 2024-01-03 | 도레이 카부시키가이샤 | 그렐린 저항성을 수반하는 악액질의 치료제 또는 예방제 |
US11897871B1 (en) | 2021-06-14 | 2024-02-13 | Scorpion Therapeutics, Inc. | Methods for treating cancer |
Also Published As
Publication number | Publication date |
---|---|
JPWO2012105475A1 (ja) | 2014-07-03 |
EP2671585A1 (en) | 2013-12-11 |
US20130310414A1 (en) | 2013-11-21 |
US9006262B2 (en) | 2015-04-14 |
EP2671585B1 (en) | 2016-07-13 |
MX2013008749A (es) | 2013-10-17 |
EP2671585A4 (en) | 2015-05-20 |
CA2825165C (en) | 2018-07-03 |
CN103327977A (zh) | 2013-09-25 |
CN103327977B (zh) | 2016-05-04 |
CA2825165A1 (en) | 2012-08-09 |
JP5929753B2 (ja) | 2016-06-08 |
ES2586655T3 (es) | 2016-10-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5929753B2 (ja) | 悪液質の治療又は予防剤 | |
JP6862404B2 (ja) | 骨髄異形成症候群を治療するためのタンパク質ホスファターゼ2a阻害剤 | |
JP2013231086A (ja) | 化学療法の強化方法 | |
JP2011520846A (ja) | 多発性骨髄腫の治療 | |
WO2011093441A1 (ja) | 胆道疾患の治療又は予防剤 | |
CA3116731A1 (en) | Combinations for immune-modulation in cancer treatment | |
WO2021079978A1 (ja) | 悪液質の治療剤又は予防剤 | |
US7652025B2 (en) | Remedies for sepsis | |
AU2012336154B2 (en) | Combination therapy for ovarian cancer | |
TW202308627A (zh) | 伴隨著飢餓素抗性之惡病體質的治療劑或預防劑 | |
JP2011513429A (ja) | 改善された抗癌治療法 | |
US20240139176A1 (en) | Methods of treating or preventing cachexia | |
EP4151207A1 (en) | Benzimidazoles for use in the treatment of conditions involving cd47 upregulation or for increasing phagocytosis of a cell | |
CN115551518B (zh) | 使用n2-喹啉或异喹啉取代的嘌呤衍生物的癌症联合疗法 | |
EP3187495A1 (en) | 3-(5-fluoroindolyl)-4-arylmaleimide compounds and their use in tumor treatment | |
JP2006306738A (ja) | 神経因性疼痛治療剤 | |
EP3021862B1 (en) | Peptide epoxyketone proteasome inhibitors in combination with pim kinase inhibitors for treatment of cancers | |
CN1944442A (zh) | 3,7,10-三取代基杂氮硅三环与5-fu的结合物制备及其药学上的用途 | |
JP2021011453A (ja) | 抗がん剤投与により生じる皮膚障害の治療又は予防剤 | |
WO2009104150A1 (en) | Combination comprising bosentan for treating ovarian cancer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 201280007167.X Country of ref document: CN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2012507744 Country of ref document: JP |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 12742214 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2825165 Country of ref document: CA |
|
REEP | Request for entry into the european phase |
Ref document number: 2012742214 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2012742214 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/A/2013/008749 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 13982578 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |